Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 322,932,768
  • Shares Outstanding, K 2,532,806
  • Annual Sales, $ 60,115 M
  • Annual Income, $ 365,000 K
  • 60-Month Beta 0.39
  • Price/Sales 5.46
  • Price/Cash Flow 42.56
  • Price/Book 8.11
Trade MRK with:

Options Overview Details

View History
  • Implied Volatility 16.54% ( -0.84%)
  • Historical Volatility 16.86%
  • IV Percentile 8%
  • IV Rank 12.63%
  • IV High 26.55% on 10/20/23
  • IV Low 15.09% on 05/17/24
  • Put/Call Vol Ratio 0.24
  • Today's Volume 22,462
  • Volume Avg (30-Day) 24,925
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 374,675
  • Open Int (30-Day) 372,504

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 2.14
  • Number of Estimates 8
  • High Estimate 2.25
  • Low Estimate 2.03
  • Prior Year -2.06
  • Growth Rate Est. (year over year) +203.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
122.70 +4.31%
on 05/30/24
132.79 -3.61%
on 05/21/24
-3.20 (-2.44%)
since 05/17/24
3-Month
120.38 +6.32%
on 03/20/24
133.10 -3.84%
on 03/27/24
+6.55 (+5.39%)
since 03/18/24
52-Week
99.14 +29.10%
on 10/19/23
133.10 -3.84%
on 03/27/24
+18.67 (+17.08%)
since 06/16/23

Most Recent Stories

More News
3 Dow Dividend Stocks Beating the Market This Year

While all eyes are still on standout AI tech stocks, these three dividend-paying Dow stocks are beating the broader market this year.

$DOWI : 38,834.86 (+0.15%)
WMT : 67.60 (+0.27%)
MRK : 127.99 (+0.38%)
AXP : 229.31 (+0.46%)
$SPX : 5,487.03 (+0.25%)
$IUXX : 19,908.86 (+0.03%)
3 Stocks That Have Soared 179% or More in 2024 and Could Go Even Higher, According to Wall Street

These high-flying stocks could have more room to run if analysts are right.

MRK : 127.99 (+0.38%)
SMMT : 7.94 (+0.51%)
SMCI : 920.01 (+3.67%)
VKTX : 50.64 (-2.65%)
Why Moderna Stock Is a No-Brainer Buy Right Now

This messenger-RNA pioneer should be able to keep its rebound going.

MRK : 127.99 (+0.38%)
MRNA : 133.27 (-3.36%)
3 Reasons to Buy Moderna Stock

The biotech hasn't said its last word.

MRK : 127.99 (+0.38%)
MRNA : 133.27 (-3.36%)
Is Merck & Company Stock Outperforming the Dow

Merck & Company has significantly outperformed the Dow Jones recently, and Wall Street analysts expect further gains for the stock.

MRK : 127.99 (+0.38%)
PFE : 27.41 (+1.59%)
$DOWI : 38,834.86 (+0.15%)
2 Dividend Stocks Billionaires Are Buying: Should You?

That's not a bad crowd to follow when investing in stocks.

PFE : 27.41 (+1.59%)
MRK : 127.99 (+0.38%)
3 Cathie Wood Biotech Stocks That Analysts Expect to Double

This article delves into three biotech stocks held in Cathie Wood's ARKK ETF that analysts expect to double in value. Investors looking to add exposure to promising biotech opportunities, with a preference...

ARKK : 43.68 (-1.02%)
NTLA : 24.80 (-1.47%)
PRME : 6.28 (-1.10%)
BEAM : 23.17 (-3.58%)
XBI : 89.70 (-0.98%)
WFC : 59.05 (+1.39%)
VKTX : 50.64 (-2.65%)
CRSP : 60.57 (-1.97%)
ABBV : 171.36 (+0.99%)
AMGN : 305.99 (+0.89%)
BMY : 40.81 (-0.39%)
GILD : 63.15 (-1.74%)
Advancements in Cancer Therapeutics: What to Expect from the Upcoming 2024 Oncology Conference

USA News Group News Commentary – As the 2024 American Society of Clinical Oncology (ASCO) annual meeting approaches, excitement builds over the latest in cancer treatment advancements, particularly in...

ONCY : 1.0200 (+0.99%)
ONC.TO : 1.39 (unch)
MRK : 127.99 (+0.38%)
RHHBY : 34.9800 (+1.16%)
AMGN : 305.99 (+0.89%)
BNTX : 86.27 (-2.45%)
Billionaire Ken Griffin Is Buying These Dividend Stocks Hand Over Fist. Should You?

The billionaire hedge fund manager doesn't need dividend income. But he'll get more of it after his Q1 purchases.

CVX : 153.33 (+0.09%)
HES : 143.33 (-0.17%)
BAC : 39.99 (+1.21%)
MRK : 127.99 (+0.38%)
Do Wall Street Analysts Like Merck & Company Stock?

As Merck outperforms the broader market this year, Wall Street analysts remain optimistic about the stock's prospects.

MRK : 127.99 (+0.38%)
$SPX : 5,487.03 (+0.25%)
XPH : 39.72 (-0.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 130.42
2nd Resistance Point 129.58
1st Resistance Point 128.78
Last Price 127.99
1st Support Level 127.14
2nd Support Level 126.30
3rd Support Level 125.50

See More

52-Week High 133.10
Last Price 127.99
Fibonacci 61.8% 120.13
Fibonacci 50% 116.12
Fibonacci 38.2% 112.11
52-Week Low 99.14

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar